Dr. Patrick J. Hensley, M.D.
Urology (Urology Physician)
740 S Limestone Ste B200
Lexington, KY 40536
Who else practices at this address →
Fayette County includes mental health (15% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of Kentucky College of Medicine (2015)
- Years since graduation
- 11
- In the NPI registry since
- 2012
- Medicare patients seen, 2024
- 247
Licensed in Texas since 2020, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2015Medical school: University of Kentucky College of Medicine
- 2012Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Urology Physician primary
KY license TP736 · KY license R3789 · TX license S4781 (first issued 2020; canc non-renewal) - Student in an Organized Health Care Education/Training Program
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Kentucky Hospital Lexington, KY
- Harrison Memorial Hospital Cynthiana, KY
Medical groups
- Kentucky Medical Services Foundation, Inc (967 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 247
- Services billed
- 875
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 113 | 84 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 65 | 30 |
| Diagnostic exam of bladder and urethra using an endoscope | 61 | 42 |
| Established patient office or other outpatient visit, 40-54 minutes | 57 | 48 |
| Established patient office or other outpatient visit, 20-29 minutes | 34 | 28 |
| New patient office or other outpatient visit, 45-59 minutes | 29 | 29 |
| New patient office or other outpatient visit, 60-74 minutes | 25 | 25 |
| Imaging of urinary tract following injection of a contrast agent | 24 | 20 |
| Insertion of stent in ureter using an endoscope | 18 | 15 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 16 | 14 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Tamsulosin Hcl Other prescribers in Lexington, KY | 48 |
| Methocarbamol Other prescribers in Lexington, KY | 26 |
| Levofloxacin Other prescribers in Lexington, KY | 22 |
| Oxybutynin Chloride Er (oxybutynin chloride) Other prescribers in Lexington, KY | 20 |
| Finasteride Other prescribers in Lexington, KY | 13 |
| Ondansetron Odt (ondansetron) Other prescribers in Lexington, KY | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 12 companies reported 54 payments worth $44,456 in total to this clinician.
| Ferring Pharmaceuticals Inc. | $17,701 |
|---|---|
| Janssen Biotech, Inc. | $13,445 |
| Janssen Global Services, LLC | $6,345 |
| Urogen Pharma, Inc. | $3,051 |
| Janssen Scientific Affairs, LLC | $3,036 |
| Boston Scientific Corporation | $356 |
| Angiodynamics, Inc. | $129 |
| Immunitybio, Inc. | $129 |
| Compensation for services other than consulting (speaking, faculty) | $23,621 |
|---|---|
| Consulting Fee | $13,899 |
| Honoraria | $2,888 |
| Food and Beverage | $2,329 |
| Travel and Lodging | $1,679 |
| Education | $41.12 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Janssen Biotech, Inc. Dec 19, 2025 | Compensation for services other than consulting (speaking, faculty) RYBREVANT; CARVYKTI · Oncology | $5,288 |
| Ferring Pharmaceuticals Inc. Jun 18, 2025 | Compensation for services other than consulting (speaking, faculty) ADSTILADRIN · ONCOLOGY | $4,275 |
| Ferring Pharmaceuticals Inc. Jul 2, 2025 | Compensation for services other than consulting (speaking, faculty) ADSTILADRIN · ONCOLOGY | $4,275 |
| Janssen Biotech, Inc. May 9, 2025 | Consulting Fee | $4,024 |
| Ferring Pharmaceuticals Inc. May 22, 2025 | Compensation for services other than consulting (speaking, faculty) ADSTILADRIN · ONCOLOGY | $3,800 |
| Janssen Global Services, LLC Sep 16, 2025 | Consulting Fee | $3,525 |
| Urogen Pharma, Inc. Oct 6, 2025 | Honoraria ZUSDURI · LG-IR-NMIBC · in-kind | $2,888 |
| Ferring Pharmaceuticals Inc. May 15, 2025 | Compensation for services other than consulting (speaking, faculty) ADSTILADRIN · ONCOLOGY | $2,850 |
| Janssen Global Services, LLC May 20, 2025 | Consulting Fee | $2,820 |
| Ferring Pharmaceuticals Inc. Apr 24, 2025 | Compensation for services other than consulting (speaking, faculty) ADSTILADRIN · ONCOLOGY | $1,900 |
All 22 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Janssen Biotech, Inc. Dec 19, 2025 | Compensation for services other than consulting (speaking, faculty) RYBREVANT; CARVYKTI · Oncology | $5,288 |
| AstraZeneca Pharmaceuticals LP Nov 19, 2025 | Education IMFINZI · Oncology · in-kind Company’s descriptionJournal Article | $35.06 |
| Janssen Biotech, Inc. Nov 7, 2025 | Travel and Lodging RYBREVANT; CARVYKTI · Oncology · travel to Orlando, FL · in-kind | $348 |
| Janssen Biotech, Inc. Nov 6, 2025 | Travel and Lodging RYBREVANT; CARVYKTI · Oncology · travel to Orlando, FL · in-kind | $19.50 |
| Urogen Pharma, Inc. Oct 6, 2025 | Honoraria ZUSDURI · LG-IR-NMIBC · in-kind | $2,888 |
| Janssen Global Services, LLC Sep 16, 2025 | Consulting Fee | $3,525 |
| Janssen Biotech, Inc. Aug 15, 2025 | Compensation for services other than consulting (speaking, faculty) RYBREVANT; CARVYKTI · Oncology | $353 |
| Ferring Pharmaceuticals Inc. Jul 2, 2025 | Compensation for services other than consulting (speaking, faculty) ADSTILADRIN · ONCOLOGY | $4,275 |
| Ferring Pharmaceuticals Inc. Jun 18, 2025 | Compensation for services other than consulting (speaking, faculty) ADSTILADRIN · ONCOLOGY | $4,275 |
| Janssen Biotech, Inc. Jun 2, 2025 | Compensation for services other than consulting (speaking, faculty) RYBREVANT; CARVYKTI · Oncology | $881 |
| Ferring Pharmaceuticals Inc. May 22, 2025 | Compensation for services other than consulting (speaking, faculty) ADSTILADRIN · ONCOLOGY | $3,800 |
| Janssen Global Services, LLC May 20, 2025 | Consulting Fee | $2,820 |
| Ferring Pharmaceuticals Inc. May 15, 2025 | Compensation for services other than consulting (speaking, faculty) ADSTILADRIN · ONCOLOGY | $2,850 |
| Janssen Biotech, Inc. May 9, 2025 | Consulting Fee | $4,024 |
| Janssen Scientific Affairs, LLC Apr 27, 2025 | Consulting Fee | $1,363 |
| Janssen Biotech, Inc. Apr 27, 2025 | Consulting Fee | $818 |
| Ferring Pharmaceuticals Inc. Apr 24, 2025 | Compensation for services other than consulting (speaking, faculty) ADSTILADRIN · ONCOLOGY | $1,900 |
| Janssen Biotech, Inc. Apr 23, 2025 | Travel and Lodging travel to DALLAS, TX · in-kind | $148 |
| Janssen Biotech, Inc. Apr 23, 2025 | Travel and Lodging travel to DALLAS, TX · in-kind | $136 |
| Janssen Biotech, Inc. Mar 21, 2025 | Travel and Lodging travel to DALLAS, TX · in-kind | $1,027 |
| Urogen Pharma, Inc. Feb 11, 2025 | Education JELMYTO · UROTHELIAL CANCER · in-kind | $6.06 |
| Janssen Scientific Affairs, LLC Jan 23, 2025 | Consulting Fee | $1,350 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 3 companies. The companies reported $94,694 in research payments for these studies, mostly to the institutions running them.
- A study of intravesical enfortumab vedotin for treatment of patients with nonmuscle invasive bladder cancer nmibc
Pfizer Inc. - Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or Fusions
Janssen Research & Development, LLC - Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer
Ferring Pharmaceuticals As · Recruiting · NCT06510374
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.